BLAINJECTIONINJECTABLE
Approved
Nov 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
44
Data completeness
7/8 — Comprehensive
FASENRA (benralizumab) by AstraZeneca is interleukin 5 receptor alpha-directed antibody interactions [moa]. Approved for interleukin-5 receptor alpha-directed cytolytic antibody [epc]. First approved in 2017.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FASENRA (benralizumab) is a monoclonal antibody that targets the interleukin-5 receptor alpha, reducing eosinophil levels in the bloodstream. It is indicated for patients with moderate-to-severe eosinophilic asthma. The drug works by blocking IL-5 signaling, thereby reducing airway inflammation and asthma exacerbations.
$0.069BPart D
PeakProduct is at peak commercial maturity with 11,680 Part D claims in 2023; brand teams should prepare for market saturation and competitive repositioning strategies.
Mechanism of Action
Interleukin 5 Receptor alpha-directed Antibody Interactions
Pharmacologic Class:
Interleukin-5 Receptor alpha-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (44)
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
Started May 2026
230 enrolled
AsthmaEosinophilic Granulomatosis With Polyangiitis (EGPA)Hypereosinophilic Syndrome (HES)
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
Started Dec 2025
335 enrolled
Severe Eosinophilic Asthma
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
Started Jul 2025
1,000 enrolled
Chronic Obstructive Pulmonary Disease
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
Started Apr 2025
14 enrolled
Eosinophilic Granulomatosis With Polyangiitis (EGPA)Hypereosinophilia Syndrome (HES)
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
Started Mar 2025
400 enrolled
Eosinophilic Asthma
Worked on FASENRA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.